Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12616001351404
Ethics application status
Approved
Date submitted
14/09/2016
Date registered
28/09/2016
Date last updated
21/07/2024
Date data sharing statement initially provided
21/07/2024
Type of registration
Prospectively registered
Titles & IDs
Public title
A single and multiple dose safety and tolerability study of oral ketamine in healthy volunteer and patients with a history of depression or anxiety.
Query!
Scientific title
A single centre, double blind, randomised , parallel group, ascending single and multiple dose, safety and tolerability, pharmacokinetic and pharmacodynamic study of oral ketamine in healthy volunteer and patients with a history of depression or anxiety cohorts.
Query!
Secondary ID [1]
290131
0
None
Query!
Universal Trial Number (UTN)
U1111-1186-0282
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Depression
300248
0
Query!
Anxiety
300284
0
Query!
Condition category
Condition code
Mental Health
300112
300112
0
0
Query!
Depression
Query!
Mental Health
300151
300151
0
0
Query!
Anxiety
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Participants will be confined at the clinical site for the duration of the dosing and sampling periods.
Cohort 1-3: Study days 0 to 4 and study days 6 to 10
Cohort 4: Study days 0 to 5
Cohort 5: Study days 0 to 2 and study days 6 to 9
Planned doses as follows:
Dose level 1 (Cohort 1 - 8 healthy volunteers): single capsule containing 60 mg oral ketamine or methylcellulose placebo on day 1, then twice daily day 7-9
Dose level 2 (Cohort 2 - 8 healthy volunteers): 2 x capsules containing 60 mg oral ketamine or methylcellulose placebo on day 1, then twice daily day 7-9
Dose level 3 (Cohort 3 - 8 healthy volunteers): 4 x capsules containing 60 mg oral ketamine or methylcellulose placebo on day 1, then twice daily day 7-9
Dose level 4 (Cohort 4 - 6 patients with depression and 6 patients with anxiety): single capsule containing 60 mg oral ketamine once daily in the morning and then 1-2x (dependant on whether or not depression or anxiety has improved along with assessments of safety and tolerability assessed by the Principal Investigator/Head of Department Psychological Medicine) 60 mg oral ketamine once daily 12 hours after the morning dose on day 1 and then 1-4x 60 mg (dependant on whether or not depression or anxiety has improved along with assessments of safety and tolerability assessed by the Principal Investigator/Head of Department Psychological Medicine) twice daily on days 2-4
Dose Level 5 (Cohort 5 - 12 healthy volunteers): Dose will be the highest single dose of oral ketamine from the results of Cohort 1 to 3 in fasted state on day 1 and fed state on day 8.
Volunteers are not required water for 1 hour prior to dosing until 1 hour after dosing (except for the water consumed with each dose).
For cohort 5 volunteers are required not to eat for 10 hours before dosing on day 1 and the a standardised high fat content meal on day 8 and to fast for approximately 4 hours after each dose.
Query!
Intervention code [1]
295884
0
Treatment: Drugs
Query!
Comparator / control treatment
Identical capsule containing methylcellulose as Placebo
Query!
Control group
Placebo
Query!
Outcomes
Primary outcome [1]
299596
0
To evaluate the pharmacokinetics (as summarised by Cmax and AUC). All plasma samples will be assayed for ketamine and norketamine using one fully validated LC/MS/MS method. Validation will be conducted to comply with FDA guidelines.
Query!
Assessment method [1]
299596
0
Query!
Timepoint [1]
299596
0
Cohort 1, 2,3:
Day 1: Sampling immediately prior to dosing and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8, 9, 10, 12, 14, 17, 20, 24, 32 & 48 hours after dosing.
Days 7-10: Sampling immediately prior to dosing, then at 12, 24, 36, 48, 48.5, 49, 49.5, 50, 50.5, 51, 51.5, 52, 52.5, 53, 54, 55, 56, 57, 58, 60, 62,65, 68 and 72 hours after the initial dose.
Cohort 4: Sampling immediately before each dose administration and around Tmax (anticipate between 3-5 hours post-dose but timepoints will be finalised based on results of cohorts 1-3)
Cohort 5: D1: Sampling immediately prior to dosing and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8, 9, 10, 12, 14, 17, 20, 24, 32 & 48 hours after dosing.
D8: Sampling immediately prior to dosing and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8, 9, 10, 12, 14, 17, 20, 24, 32 & 48 hours after dosing.
Query!
Primary outcome [2]
299597
0
To evaluate the pharmadynamics (as summarised by BDNF). All serum samples will be assayed using a fully validated ELISA method. Validation will be conducted to comply with FDA guidelines.
Query!
Assessment method [2]
299597
0
Query!
Timepoint [2]
299597
0
Cohort 1, 2,3:
Day 1 at 0 and 24 hours and Days 7-10 at 0, 24 and 72 hours
Days 7 to 10: 0, 3, 12, 24, 36, 48, 72h
Cohort 4:
Days 1-4 at 0, 24, 72 and 96 hours.
Query!
Primary outcome [3]
299631
0
To evaluate the safety (as summarised by adverse events, vital signs and ECG).
Query!
Assessment method [3]
299631
0
Query!
Timepoint [3]
299631
0
Adverse events will be assessed continuously from dosing until release from confinement period in each cohort.
Vital signs will be:
Cohort 1,2,3, Day 1: 0, 1, 2, 3, 6, 12, 15, 18, 24, 27, 30, 36, 48h and Days 7 to 10: 0, 1, 2, 3, 6, 12, 15, 18, 24, 27, 30, 36, 48, 72h
Cohort 4 has additional time points of 84 and 96 hours
Cohort 5, Day 1 & 8: 0, 1, 2, 3, 6, 12, 15, 18, 24, 27, 30, 36, 48h
12-Lead ECGs:
Cohort 1,2,3, day 1: 0, 3, 12, 24, 36, 48h and days 7 to 10: 0, 3, 12, 24, 36, 48, 72h
Cohort 4 has additional time points of 84 and 96 hours
Cohort 5, Day 1 & 8: 0, 3, 12, 24, 36, 48h
Query!
Secondary outcome [1]
327715
0
Time to maximum peak concentration (Tmax) will be determined by plasma sample analysis. Tmax will be the time where the maximum concentration occurred in the sample points.
Query!
Assessment method [1]
327715
0
Query!
Timepoint [1]
327715
0
Cohort 1, 2,3:
Day 1: Sampling immediately prior to dosing and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8, 9, 10, 12, 14, 17, 20, 24, 32 & 48 hours after dosing.
Days 7-10: Sampling immediately prior to dosing, then at 12, 24, 36, 48, 48.5, 49, 49.5, 50, 50.5, 51, 51.5, 52, 52.5, 53, 54, 55, 56, 57, 58, 60, 62,65, 68 and 72 hours after the initial dose.
Cohort 4: Sampling immediately before each dose administration and around Tmax (anticipate between 3-5 hours post-dose but timepoints will be finalised based on results of cohorts 1-3)
Cohort 5: D1: Sampling immediately prior to dosing and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8, 9, 10, 12, 14, 17, 20, 24, 32 & 48 hours after dosing.
D8: Sampling immediately prior to dosing and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8, 9, 10, 12, 14, 17, 20, 24, 32 & 48 hours after dosing.
Query!
Secondary outcome [2]
327959
0
Additional Primary Outcome: To evaluate efficacy (as summarised by questionnaires and rating scores (CADSS and C-SSRS)).
Query!
Assessment method [2]
327959
0
Query!
Timepoint [2]
327959
0
The following Questionnaires and Rating Scales will be used at the times indicated:
CADSS
Cohort 1-3, Day 1: 0, 3, 12, 24, 36, 48h and days 7 to 10: 0, 3, 12, 24, 36, 48, 72h
Cohort 4 has additional time points of 84 and 96 hours
Cohort 5, Day 1 & 8: 0, 3, 12, 24, 36, 48h
C-SSRS
Cohort 1-3, day 1: 0, 24, 48h and days 7 to 10: 0, 24, 48, 72h
Cohort 4 has additional time points of 96 hours
Cohort 5, days 1 and 8: 0, 24, 48h
Query!
Eligibility
Key inclusion criteria
Subjects will be eligible for enrolment for Cohorts 1, 2, 3 and 5: on the basis of:
a) Provide written informed consent
b) Male or non-pregnant females
c) Aged 18 to 55 years on the day of consent
d) Body Mass Index greater than 18 and less than 30kg/m2 on day of consent
e) Healthy individuals as determined by medical history, physical examination, ECG, vital signs and laboratory tests
f) HIV and Hepatitis B and C negative
g) Non-smoker (for at least 6 months prior to the date of consent).
h) Drug free as determined by urine drug testing
Subjects will be eligible for enrolment for Cohort 4 on the basis of:
a) Provide written informed consent
b) Male or non-pregnant females
c) Aged 18 to 60 years on the day of consent
d) Body Mass Index greater than 18 and less than 35 kg/m2 on day of consent
e) Healthy individuals as determined by medical history, physical examination, ECG, vital signs and laboratory tests
f) HIV and Hepatitis B and C negative
g) Previously Diagnosed DSM-5 Major Depressive Disorder (MDD) (n=6) or Generalized Anxiety Disorder (GAD) /Social Anxiety Disorder (SAD) (n=6)
h) An inadequate response, ie treatment was not successful, treatment with at least 2 prescribed antidepressants
i) MADRS score of at least 20 (MDD) or HAM-A score of 18 (GAD/SAD)
j) Psychotropic medication and/or psychotherapy regime is stable i.e no change to drugs or dose or visit schedule within previous four weeks
k) Previous positive response to off label SC injection ketamine use as determined by documentation of a 50% change in previous Hamilton Anxiety Scale (HAM-A) for MDD, Spielberger State Anxiety inventory (SSAI) plus Fear Questionnaire (FQ) for SAD
l) Drug free as determined by urine drug testing
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
60
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
Yes
Query!
Key exclusion criteria
Subjects will be excluded for Cohorts 1, 2, 3 and 5: on the basis of:
a) Evidence from medical history, physical or laboratory examinations of clinically significant neurologic, psychiatric, cardiac, respiratory, renal, hepatic, endocrine, gastrointestinal, immunological condition or any other diagnosed conditions that might interfere with the absorption, distribution, metabolism or excretion of the drug, interfere with the ability to accurately record study measurements or which may potentiate or predispose to undesired effects.
b) Participants receiving treatment with monoamine oxidase inhibitors, vasoconstriction agents, thyroxine or benzodiazepines.
c) Any clinically significant history of alcohol or drug abuse or dependency including ketamine or its excipients.
d) Any clinically significant illness in the 30 days prior to dosing day 1.
e) Any clinically significant infection or febrile illness in the five days prior to dosing day 1.
f) Clinically significant Abnormal ECG at the screening visit
g) Females who are pregnant or breastfeeding
h) Females who are not using effective contraception for the prevention of pregnancy ie prescribed hormonal contraceptives or other reliable methods
i) Participation in any drug study in the 60 days preceding dosing day 1
j) Participants who do not consent to their GP being contacted prior to the commencement of the study, if necessary, about their medical history or after the study about any adverse results or reactions
k) Participants who, in the opinion of the Investigator, do not understand the information and procedures of the study, or would not be compliant with them (in particular the study restrictions and risks involved).
l) Any participation for whom the Investigator believes, for any reason, inclusion would not be an acceptable risk
m) Subject with any clinically significant abnormality or abnormal laboratory test results found during medical screening
n) History of mental illness requiring medication or treatment by a physician
Subjects will be excluded for Cohort 4: on the basis of:
a) Evidence from medical history, physical or laboratory examinations of clinically significant neurologic, cardiac, respiratory, renal, hepatic, endocrine, gastrointestinal, immunological condition or any other diagnosed conditions that might interfere with the absorption, distribution, metabolism or excretion of the drug, interfere with the ability to accurately record study measurements or which may potentiate or predispose to undesired effects.
b) Participants receiving treatment with monoamine oxidase inhibitors, vasoconstriction agents, thyroxine or benzodiazepines.
c) Any clinically significant history of alcohol or drug abuse or dependency.
d) Any clinically significant illness in the 30 days prior to dosing day 1.
e) Any clinically significant infection or febrile illness in the five days prior to dosing day 1.
f) Clinically significant Abnormal ECG at the screening visit
g) Females who are pregnant or breastfeeding
h) Females who are not using effective contraception for the prevention of pregnancy ie prescribed hormonal contraceptives or other reliable methods
i) Participation in any drug study in the 60 days preceding dosing day 1
j) Participants who do not consent to their GP being contacted prior to the commencement of the study, if necessary, about their medical history or after the study about any adverse results or reactions
k) Participants who, in the opinion of the Investigator, do not understand the information and procedures of the study, or would not be compliant with them (in particular the study restrictions and risks involved).
l) Any participation for whom the Investigator believes, for any reason, inclusion would not be an acceptable risk
m) Subject with any clinically significant abnormality or abnormal laboratory test results found during medical screening
n) Past or current history of schizophrenia, bipolar disorder, or other psychotic disorder
o) History of abuse of ketamine or phencyclidine
p) Significant current risk of suicide as assessed by C-SSRS
q) Contraindication to the use of ketamine, e.g., any condition in which a significant elevation of blood pressure would be hazardous, such as decompensated heart failure, severe or poorly controlled hypertension (blood pressure systolic less than or equal to 160 or diastolic less than or equal to 90, tested on 2 or more occasions); within last 3 months, recent myocardial infarction, stroke, cerebral haemorrhage; myasthenia gravis.
r) History of neurogenerative disorder eg Alzheimers disease, vascular dementia, Parkinson's disease or evidence of mild cognitive impairment
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
After obtaining consent and confirming eligibility,the participant will be randomised in the study. Study drug will be prepared for each participant by pharmacy staff, according to the randomisation code. All clinical staff will remain blinded. Individual randomisation envelopes will be provided in case the identity of study drug administered to a participant needs to be known.
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Simple randomization by computer
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 1
Query!
Type of endpoint/s
Safety/efficacy
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Date of first participant enrolment
Anticipated
29/09/2016
Query!
Actual
8/10/2016
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
1/04/2017
Query!
Date of last data collection
Anticipated
Query!
Actual
24/04/2017
Query!
Sample size
Target
48
Query!
Accrual to date
Query!
Final
43
Query!
Recruitment outside Australia
Country [1]
8224
0
New Zealand
Query!
State/province [1]
8224
0
Otago
Query!
Funding & Sponsors
Funding source category [1]
294506
0
Commercial sector/Industry
Query!
Name [1]
294506
0
Douglas Pharmaceuticals Limited
Query!
Address [1]
294506
0
PO Box 45 027
Auckland 0651
Query!
Country [1]
294506
0
New Zealand
Query!
Primary sponsor type
Commercial sector/Industry
Query!
Name
Zenith Technology Corp Ltd
Query!
Address
PO Box 1777
156 Frederick St
Dunedin 9054
Query!
Country
New Zealand
Query!
Secondary sponsor category [1]
293371
0
None
Query!
Name [1]
293371
0
Query!
Address [1]
293371
0
Query!
Country [1]
293371
0
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
295939
0
Southern Health and Disability Ethics Committee
Query!
Ethics committee address [1]
295939
0
Freyberg Building 20 Aitken Street PO Box 5013 Wellington 6011
Query!
Ethics committee country [1]
295939
0
New Zealand
Query!
Date submitted for ethics approval [1]
295939
0
04/08/2016
Query!
Approval date [1]
295939
0
13/09/2016
Query!
Ethics approval number [1]
295939
0
16/STH/121
Query!
Summary
Brief summary
This study will investigate the safety and tolerability of ketamine given to healthy volunteers and patients with a history of depression and anxiety. It will examine how the drug is absorbed and excreted from the body. The study will also examine what effects ketamine has on specific functions of the body.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
68974
0
Dr Paul W Glue
Query!
Address
68974
0
Department of Psychologist Medicine
University of Otago
PO Box 913
Dunedin 9054
Query!
Country
68974
0
New Zealand
Query!
Phone
68974
0
+64 3 470 3867
Query!
Fax
68974
0
+6434779605
Query!
Email
68974
0
[email protected]
Query!
Contact person for public queries
Name
68975
0
Linda Folland
Query!
Address
68975
0
Zenith Technology Corp Ltd
PO Box 1777
156 Frederick St
Dunedin 9054
Query!
Country
68975
0
New Zealand
Query!
Phone
68975
0
+6434779669
Query!
Fax
68975
0
+6434779605
Query!
Email
68975
0
[email protected]
Query!
Contact person for scientific queries
Name
68976
0
Tak Hung
Query!
Address
68976
0
Zenith Technology Corp Ltd
PO Box 1777
156 Frederick St
Dunedin 9054
Query!
Country
68976
0
New Zealand
Query!
Phone
68976
0
+6434779669
Query!
Fax
68976
0
+6434779605
Query!
Email
68976
0
[email protected]
Query!
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
Query!
No/undecided IPD sharing reason/comment
All data will be compiled into a final report that is the property of the sponsor company. All participant data will be provided in summary format and result of the study only will be reported.
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
Source
Title
Year of Publication
DOI
Embase
Safety and efficacy of extended release ketamine tablets in patients with treatment-resistant depression and anxiety: open label pilot study.
2020
https://dx.doi.org/10.1177/2045125320922474
N.B. These documents automatically identified may not have been verified by the study sponsor.
Download to PDF